CA3171883C - Compositions and methods for treating neuropsychiatric disorders using an endothelin-b receptor agonist - Google Patents

Compositions and methods for treating neuropsychiatric disorders using an endothelin-b receptor agonist Download PDF

Info

Publication number
CA3171883C
CA3171883C CA3171883A CA3171883A CA3171883C CA 3171883 C CA3171883 C CA 3171883C CA 3171883 A CA3171883 A CA 3171883A CA 3171883 A CA3171883 A CA 3171883A CA 3171883 C CA3171883 C CA 3171883C
Authority
CA
Canada
Prior art keywords
endothelin
receptor agonist
etb
brain
irl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3171883A
Other languages
English (en)
French (fr)
Other versions
CA3171883A1 (en
Inventor
Anil Gulati
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Midwestern University Glendale
Original Assignee
Midwestern University Glendale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Midwestern University Glendale filed Critical Midwestern University Glendale
Publication of CA3171883A1 publication Critical patent/CA3171883A1/en
Application granted granted Critical
Publication of CA3171883C publication Critical patent/CA3171883C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2285—Endothelin, vasoactive intestinal contractor [VIC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA3171883A 2013-07-08 2014-07-08 Compositions and methods for treating neuropsychiatric disorders using an endothelin-b receptor agonist Active CA3171883C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361843702P 2013-07-08 2013-07-08
US61/843,702 2013-07-08
US201361902935P 2013-11-12 2013-11-12
US61/902,935 2013-11-12
CA2917325A CA2917325C (en) 2013-07-08 2014-07-08 Compositions and methods for treating neuropsychiatric disorders using an endothelin-b receptor agonist

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2917325A Division CA2917325C (en) 2013-07-08 2014-07-08 Compositions and methods for treating neuropsychiatric disorders using an endothelin-b receptor agonist

Publications (2)

Publication Number Publication Date
CA3171883A1 CA3171883A1 (en) 2015-01-15
CA3171883C true CA3171883C (en) 2024-03-05

Family

ID=52280704

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3171883A Active CA3171883C (en) 2013-07-08 2014-07-08 Compositions and methods for treating neuropsychiatric disorders using an endothelin-b receptor agonist
CA2917325A Active CA2917325C (en) 2013-07-08 2014-07-08 Compositions and methods for treating neuropsychiatric disorders using an endothelin-b receptor agonist

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2917325A Active CA2917325C (en) 2013-07-08 2014-07-08 Compositions and methods for treating neuropsychiatric disorders using an endothelin-b receptor agonist

Country Status (10)

Country Link
US (2) US10561704B2 (enExample)
EP (1) EP3019242B1 (enExample)
JP (2) JP6928450B2 (enExample)
CN (2) CN105682741A (enExample)
AU (1) AU2014287427B2 (enExample)
BR (1) BR112016000431A8 (enExample)
CA (2) CA3171883C (enExample)
ES (1) ES2825101T3 (enExample)
PL (1) PL3019242T3 (enExample)
WO (1) WO2015006324A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2424529T3 (pl) 2009-04-30 2017-06-30 Midwestern University Nowe postępowania terapeutyczne z zastosowaniem centakwiny
CN112469474A (zh) 2018-05-03 2021-03-09 美国中西部大学 出血和centhaquin引起的复苏后内皮素受体的变化
US20240207356A1 (en) * 2022-12-26 2024-06-27 Pharmazz, Inc. Composition and method for wound healing and repair of damaged nerves
WO2024222663A1 (zh) * 2023-04-26 2024-10-31 拜西欧斯（北京）生物技术有限公司 多肽及其应用
US20250000934A1 (en) 2023-06-28 2025-01-02 Pharmazz, Inc. Lyophilized sovateltide-based injectable formulation and method for preparation thereof
WO2026086901A1 (zh) * 2024-10-25 2026-04-30 拜西欧斯（北京）生物技术有限公司 用于治疗神经系统疾病的多肽药物组合物及其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3954987A (en) 1972-12-22 1976-05-04 Sandoz, Inc. 2-Alkyl-4-substituted amino-quinazolines and nitrates thereof in the treatment of myocardial shock
US3983121A (en) 1974-07-01 1976-09-28 Council Of Scientific And Industrial Research 1-Substituted 4-(β-2-quinolylethyl)piperazines and 1,2,3,4-tetrahydroquinolyl-ethyl analogues thereof
DE2557784C2 (de) 1975-12-22 1986-04-17 Hoechst Ag, 6230 Frankfurt Forskolin, Verfahren zu dessen Gewinnung und diese Verbindung enthaltende pharmazeutische Präparate
US4761417A (en) 1982-05-14 1988-08-02 Maroko Peter R Compounds, compositions and method of treatments for improving circulatory performance
US5055470A (en) 1989-06-01 1991-10-08 Bristol-Myers Squibb Co. Method of treatment of ischemia in brain
US5922681A (en) 1992-09-14 1999-07-13 Warner-Lambert Company Endothelin antagonists
US20040063719A1 (en) 1998-08-26 2004-04-01 Queen's University At Kingston Combination therapy using antihypertensive agents and endothelin antagonists
US6545048B1 (en) * 1999-06-29 2003-04-08 California Institute Of Technology Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity
US6113915A (en) 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
SE0004455D0 (sv) * 2000-12-01 2000-12-01 Milos Pekny Method for neuron regeneration in the central nervous system
US6573285B2 (en) 2000-12-21 2003-06-03 Bristol-Myers Squibb Co. Method for preventing or treating pain by administering an endothelin antagonist
US20030232787A1 (en) 2001-05-08 2003-12-18 Dooley David James Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic
US20030104976A1 (en) 2001-07-23 2003-06-05 Gudarz Davar Analgesic methods using endothelin receptor ligands
US7030082B2 (en) 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US7973064B2 (en) 2001-11-27 2011-07-05 The Board Of Trustees Of The University Of Illinois Method and composition for potentiating an opiate analgesic
US7351692B2 (en) 2002-06-19 2008-04-01 The Board Of Trustees Of The University Of Illinois Method and composition for potentiating the antipyretic action of a nonopioid analgesic
CN1729012B (zh) 2002-10-24 2013-05-22 伊利诺伊大学评议会 治疗实体瘤的组合物
US20050009847A1 (en) * 2002-11-20 2005-01-13 Goran Bertilsson Compounds and methods for increasing neurogenesis
WO2008043102A2 (en) 2006-10-06 2008-04-10 Transition Therapeutics Inc. Vasoactive intestinal polypeptide compositions
JP2009530407A (ja) * 2006-03-23 2009-08-27 アミリン・ファーマシューティカルズ，インコーポレイテッド 代謝性疾患の治療用のエンドセリン及びエンドセリン受容体アゴニスト
PL2182977T3 (pl) * 2007-08-21 2017-01-31 Midwestern University Kompozycje do leczenia udaru lub incydentów mózgowo-naczyniowych za pomocą agonisty receptora endoteliny B
CN101374259B (zh) * 2007-08-22 2012-08-08 华为技术有限公司 实现多媒体彩铃和多媒体彩像业务的方法和装置
KR101418941B1 (ko) * 2011-04-04 2014-07-15 서울대학교병원 엔도텔린을 유효성분으로 함유하는 허혈성질환 치료용 조성물

Also Published As

Publication number Publication date
ES2825101T3 (es) 2021-05-14
US10561704B2 (en) 2020-02-18
JP2016523969A (ja) 2016-08-12
EP3019242A4 (en) 2017-01-25
EP3019242A2 (en) 2016-05-18
BR112016000431A8 (pt) 2018-01-23
CA2917325A1 (en) 2015-01-15
WO2015006324A2 (en) 2015-01-15
AU2014287427B2 (en) 2019-11-21
WO2015006324A3 (en) 2015-11-05
WO2015006324A8 (en) 2016-01-28
CN105682741A (zh) 2016-06-15
AU2014287427A1 (en) 2016-02-11
US20160151450A1 (en) 2016-06-02
PL3019242T3 (pl) 2021-02-08
JP6928450B2 (ja) 2021-09-01
JP7385924B2 (ja) 2023-11-24
CA2917325C (en) 2023-09-05
CA3171883A1 (en) 2015-01-15
CN113384701A (zh) 2021-09-14
JP2021020945A (ja) 2021-02-18
EP3019242B1 (en) 2020-08-19
US20200353031A1 (en) 2020-11-12

Similar Documents

Publication Publication Date Title
JP7385924B2 (ja) エンドセリンｂ受容体アゴニストを用いた、神経精神疾患を治療するための組成物
US8143221B2 (en) Use of ADNF polypeptides for treating peripheral neurotoxicity
Sotthibundhu et al. Aβ1–42 stimulates adult SVZ neurogenesis through the p75 neurotrophin receptor
Faivre et al. D-Ala2GIP facilitated synaptic plasticity and reduces plaque load in aged wild type mice and in an Alzheimer's disease mouse model
Gratuze et al. Mutual relationship between tau and central insulin signalling: consequences for AD and tauopathies?
Pankiewicz et al. APOE genotype differentially modulates effects of anti-Aβ, passive immunization in APP transgenic mice
Alvarez et al. Ectopic endometrium-derived leptin produces estrogen-dependent chronic pain in a rat model of endometriosis
Fujimaki et al. The regulation of stem cell aging by Wnt signaling
Zheng et al. Exercise improves recovery after ischemic brain injury by inducing the expression of angiopoietin-1 and Tie-2 in rats
Saul et al. Abundant pyroglutamate-modified ABri and ADan peptides in extracellular and vascular amyloid deposits in familial British and Danish dementias
Nelson Peripheral pathways to neurovascular unit dysfunction, cognitive impairment, and Alzheimer’s disease
Leung et al. Microglia activation mediates fibrillar amyloid-β toxicity in the aged primate cortex
JP2025142087A (ja) アルファ－シヌクレインの調節因子
GB2571978A (en) Uses, compositions and methods
Hung et al. FGFR1 agonists alleviate pathology and cognitive impairment in an Alzheimer's disease mouse model
US11105815B2 (en) Compositions and methods for enhancing neuro-repair
Cantara et al. Opposite effects of beta amyloid on endothelial cell survival: role of fibroblast growth factor-2 (FGF-2)
US20130065825A1 (en) Compositions and Methods for Delaying Senescence or Cell Death in Neurons
Urrutia et al. Inflaming the Brain with Iron. Antioxidants 2021, 10, 61
Yang et al. Investigating the impact of dysregulated brain metabolism on synaptic and cognitive outcomes
Johnson IGF-1-Mediated Reinforcement of the Blood Brain Barrier During Ischemia-reperfusion in Middle-Aged Female Rats
Watson Obesity and the Hippocampus: How Diet-Induced Insulin Resistance Contributes to Memory Impairment
Trigiani Benefits of Physical Exercise on Cognitive, White Matter, and Endothelial Dysfunctions in Mouse Models of Vascular Cognitive Impairment and Dementia
WO2014192000A1 (en) Compositions and methods for treatment of retinal degenerative diseases
Ivanco et al. Cerebral angiogenic factors, angiogenesis, and physiological response to chronic hypoxia differ amongst four commonly used mouse strains.

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220830

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250707

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250707

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U107 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REFUND REQUEST RECEIVED

Effective date: 20250729

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260707

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260707